Abstract
A phase II study of tislelizumab (T) monotherapy as neoadjuvant treatment for cisplatin-ineligible high risk upper tract urothelial carcinoma (UTUC).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have